SCHEMBL3244606

SCHEMBL3244606

CCC(CC)(C(NC(=O)c1c(C)cccc1OC)c1ccccc1)N(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 2/20 0.44
TAS1R1 Q7RTX1 2/20 0.44
TAS1R2 Q8TE23 1/20 0.44
ATM Q13315 1/20 0.41
ALDH1A1 P00352 2/20 0.39
HPGD P15428 1/20 0.39
TACR3 P29371 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
SLC6A9 P48067 3/20 0.38
MAPK1 P28482 2/20 0.38
MAPT P10636 1/20 0.38
GFER P55789 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
TSHR P16473 1/20 0.37
MEN1 O00255 1/20 0.37
CRHBP P24387 1/20 0.37
KMT2A Q03164 1/20 0.37
CRHR2 Q13324 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3238502 0.90 L3MBTL1 (0.47) ALDH1A1L3MBTL1SLC6A9MEN1KMT2A
SCHEMBL3905138 0.86 ATM (0.44) TAS1R3TAS1R1TAS1R2ATMALDH1A1
SCHEMBL3232912 0.84 ITGB1 (0.41) ALDH1A1L3MBTL1SLC6A9MAPK1
SCHEMBL3245099 0.81 SMN1; SMN2 (0.46) ALDH1A1HPGDL3MBTL1SLC6A9MAPT
SCHEMBL8265484 0.80 ATM (0.44) TAS1R3TAS1R1TAS1R2ATMALDH1A1
SCHEMBL3238177 0.79 TAS1R3 (0.41) TAS1R3TAS1R1TAS1R2ATMALDH1A1
SCHEMBL3238820 0.79 SLC6A9 (0.41) TAS1R3TAS1R1TAS1R2ATMALDH1A1
SCHEMBL3241869 0.78 SLC6A9 (0.49) SLC6A9
SCHEMBL3237956 0.77 L3MBTL1 (0.46) ALDH1A1L3MBTL1SLC6A9
SCHEMBL3907148 0.76 SLC6A9 (0.47) ALDH1A1L3MBTL1SLC6A9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-7745642-B2 Glycine transport inhibitors GLAXO GROUP LIMITED (GB) 2010-06-29 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287547-A1 Glycine Transport Inhibitors GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287547-A1 Glycine Transport Inhibitors SLC18A2, SLC6A5, SLC1A2 TAS1R3 3167/4885TAS1R1 2565/4885TAS1R2 3054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.